Kim-Mitsuyama, Shokei
Soejima, Hirofumi
Yasuda, Osamu
Node, Koichi https://orcid.org/0000-0002-2534-0939
Jinnouchi, Hideaki
Yamamoto, Eiichiro
Sekigami, Taiji
Ogawa, Hisao
Matsui, Kunihiko
Article History
Received: 27 September 2017
Accepted: 25 January 2018
First Online: 16 February 2018
Competing Interests
: Shokei Kim-Mitsuyama has received consultancy fees/honoraria/research grant from Astellas, Daiichi-Sankyo, and Takeda. Osamu Yasuda has received consultancy fees/honoraria/research grant from Otsuka Pharmaceutical Co., Ltd and Sanwa Kagaku Kenkyusho Co., Ltd. Koichi Node has received consultancy fees/honoraria/research grant from Boerhinger Ingelheim. Hideaki Jinnouchi has received consultancy fees/honoraria/research grant from AstraZeneca Pharmaceuticals, Astellas Pharma, Boehringer Ingelheim, Daiichi-sankyo, Eli Lilly, Takeda, Novartis Pharmaceuticals, Novo Nordisk and Sanofi. Kunihiko Matsui has received consultancy fees/honoraria/research grant from Daiici-Sankyo, Japan Boehringer-Ingelheim. All other coauthors declare that they have no financial competing interests.